RxDoctor Payments Data

Syed Abdul Basit, MD

Gastroenterology · Las Vegas, NVNPI 1942509492

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.3% of the total across 367 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by AbbVie at 47.9% of the total.

$6,994in general payments, 2019–2025

Across 367 payments — averaging $19.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$774
  • Takeda Pharmaceuticals U.S.A., Inc.$385
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$343
  • Gilead$291
  • Sanofi$288
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$6,80497%
  • Education$1903%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,994 in reported general payments places this provider in the 70th percentile of 103 gastroenterology providers in Nevada.

See all gastroenterology providers in Nevada

Medicare billing

Part B allowed, 2024
$249,256
Medicare patients
627
Services billed
2,203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide31$24,615
CreonLipase/Protease/Amylase14$14,439
Colestipol Hcl56$3,805
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates71$3,782
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl240$3,335
Omeprazole355$3,078
SutabSod Sulf/Pot Chloride/Mag Sulf11$1,782
Dicyclomine Hcl128$1,236
Lubiprostone17$1,065
Ursodiol12$895
Mesalamine12$807
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl39$623
Duloxetine Hcl44$500
Mirtazapine25$455
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl21$331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$3,351$39,05345 claims
Braintree Laboratories, Inc.Sutab$114$1,78211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 103 gastroenterology providers in Nevada.

Other gastroenterology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →